Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of emapalumab in macrophage activation syndrome.
De Benedetti F, Grom AA, Brogan PA, Bracaglia C, Pardeo M, Marucci G, Eleftheriou D, Papadopoulou C, Schulert GS, Quartier P, Antón J, Laveille C, Frederiksen R, Asnaghi V, Ballabio M, Jacqmin P, de Min C. De Benedetti F, et al. Among authors: jacqmin p. Ann Rheum Dis. 2023 Jun;82(6):857-865. doi: 10.1136/ard-2022-223739. Epub 2023 Mar 31. Ann Rheum Dis. 2023. PMID: 37001971 Free PMC article.
Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID-19 vaccine Ad26.COV2.S in humans.
Dari A, Jacqmin P, Iwaki Y, Neyens M, Le Gars M, Sadoff J, Hardt K, Ruiz-Guiñazú J, Pérez-Ruixo JJ. Dari A, et al. Among authors: jacqmin p. CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1485-1498. doi: 10.1002/psp4.13025. Epub 2023 Sep 15. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37715342 Free PMC article.
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.
Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C, Rao A, Degar B, Garrington TP, Sevilla J, Putti MC, Fagioli F, Ahlmann M, Dapena Diaz JL, Henry M, De Benedetti F, Grom A, Lapeyre G, Jacqmin P, Ballabio M, de Min C. Locatelli F, et al. Among authors: jacqmin p. N Engl J Med. 2020 May 7;382(19):1811-1822. doi: 10.1056/NEJMoa1911326. N Engl J Med. 2020. PMID: 32374962 Free article. Clinical Trial.
Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study.
Monnet E, Choy EH, McInnes I, Kobakhidze T, de Graaf K, Jacqmin P, Lapeyre G, de Min C. Monnet E, et al. Among authors: jacqmin p. Ann Rheum Dis. 2020 Mar;79(3):316-323. doi: 10.1136/annrheumdis-2019-216487. Epub 2019 Dec 31. Ann Rheum Dis. 2020. PMID: 31892533 Free article. Clinical Trial.
72 results